Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elgene Lim

Showing results (41-50 of 130) with videos related to

Pageof 13
Sort By:
Bioinformatics (Oxford, England)|July 9, 2010
ROAST: rotation gene set tests for complex microarray experimentsDi Wu, Elgene Lim, François Vaillant, et al.
ANZ Journal of Surgery|July 4, 2006
The influence of language spoken on colorectal cancer diagnosis and managementJeremy Rodrigues, Elgene Lim, Steven McLaughlin, et al.
Drug Discovery Today|December 17, 2019
Targeting CDK2 in cancer: challenges and opportunities for therapySolomon Tadesse, Abel T Anshabo, Neil Portman, et al.
Clinical Endocrinology|May 10, 2018
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of AustraliaMathis Grossmann, Sabashini K Ramchand, Frances Milat, et al.
Clinical Endocrinology|June 11, 2020
Testosterone therapy considerations in oestrogen, progesterone and androgen receptor-positive breast cancer in a transgender manMelanie Light, Thomas McFarlane, Andrew Ives, et al.
Expert Opinion on Investigational Drugs|January 29, 2026
Optimizing dose selection in oncology: the rationale for the clinical dose selection of giredestrant, an oral selective estrogen receptor degraderElgene Lim, Jiajie Yu, Chunze Li, et al.
Cancers|May 14, 2022
Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-ClonesRiley J Morrow, Amr H Allam, Belinda Yeo, et al.
Asia-Pacific Journal of Clinical Oncology|October 6, 2018
Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancerElgene Lim, Jane Beith, Frances Boyle, et al.
Asia-Pacific Journal of Clinical Oncology|January 31, 2026
Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in AustraliaAndrew Redfern, Elgene Lim, Sunil Lakhani, et al.
The Medical Journal of Australia|July 19, 2019
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summaryMathis Grossmann, Sabashini K Ramchand, Frances Milat, et al.
Pageof 13

Showing results (41-50 of 130) with videos related to

Sort By:
Pageof 13
Bioinformatics (Oxford, England)|July 9, 2010
ROAST: rotation gene set tests for complex microarray experimentsDi Wu, Elgene Lim, François Vaillant, et al.
ANZ Journal of Surgery|July 4, 2006
The influence of language spoken on colorectal cancer diagnosis and managementJeremy Rodrigues, Elgene Lim, Steven McLaughlin, et al.
Drug Discovery Today|December 17, 2019
Targeting CDK2 in cancer: challenges and opportunities for therapySolomon Tadesse, Abel T Anshabo, Neil Portman, et al.
Clinical Endocrinology|May 10, 2018
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of AustraliaMathis Grossmann, Sabashini K Ramchand, Frances Milat, et al.
Clinical Endocrinology|June 11, 2020
Testosterone therapy considerations in oestrogen, progesterone and androgen receptor-positive breast cancer in a transgender manMelanie Light, Thomas McFarlane, Andrew Ives, et al.
Expert Opinion on Investigational Drugs|January 29, 2026
Optimizing dose selection in oncology: the rationale for the clinical dose selection of giredestrant, an oral selective estrogen receptor degraderElgene Lim, Jiajie Yu, Chunze Li, et al.
Cancers|May 14, 2022
Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-ClonesRiley J Morrow, Amr H Allam, Belinda Yeo, et al.
Asia-Pacific Journal of Clinical Oncology|October 6, 2018
Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancerElgene Lim, Jane Beith, Frances Boyle, et al.
Asia-Pacific Journal of Clinical Oncology|January 31, 2026
Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in AustraliaAndrew Redfern, Elgene Lim, Sunil Lakhani, et al.
The Medical Journal of Australia|July 19, 2019
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summaryMathis Grossmann, Sabashini K Ramchand, Frances Milat, et al.
Pageof 13